JP2017534673A5 - - Google Patents

Download PDF

Info

Publication number
JP2017534673A5
JP2017534673A5 JP2017533742A JP2017533742A JP2017534673A5 JP 2017534673 A5 JP2017534673 A5 JP 2017534673A5 JP 2017533742 A JP2017533742 A JP 2017533742A JP 2017533742 A JP2017533742 A JP 2017533742A JP 2017534673 A5 JP2017534673 A5 JP 2017534673A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
glutathione
modulator compound
glutathione peroxidase
cyclodextrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017533742A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017534673A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/050255 external-priority patent/WO2016044314A1/en
Publication of JP2017534673A publication Critical patent/JP2017534673A/ja
Publication of JP2017534673A5 publication Critical patent/JP2017534673A5/ja
Priority to JP2021130488A priority Critical patent/JP2021181473A/ja
Priority to JP2023168970A priority patent/JP2023169413A/ja
Pending legal-status Critical Current

Links

JP2017533742A 2014-09-15 2015-09-15 精神病性障害を治療するための方法および組成物 Pending JP2017534673A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021130488A JP2021181473A (ja) 2014-09-15 2021-08-10 精神病性障害を治療するための方法および組成物
JP2023168970A JP2023169413A (ja) 2014-09-15 2023-09-29 精神病性障害を治療するための方法および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462050635P 2014-09-15 2014-09-15
US62/050,635 2014-09-15
PCT/US2015/050255 WO2016044314A1 (en) 2014-09-15 2015-09-15 Methods and compositions for treating psychotic disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021130488A Division JP2021181473A (ja) 2014-09-15 2021-08-10 精神病性障害を治療するための方法および組成物

Publications (2)

Publication Number Publication Date
JP2017534673A JP2017534673A (ja) 2017-11-24
JP2017534673A5 true JP2017534673A5 (https=) 2018-10-25

Family

ID=55533760

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017533742A Pending JP2017534673A (ja) 2014-09-15 2015-09-15 精神病性障害を治療するための方法および組成物
JP2021130488A Pending JP2021181473A (ja) 2014-09-15 2021-08-10 精神病性障害を治療するための方法および組成物
JP2023168970A Pending JP2023169413A (ja) 2014-09-15 2023-09-29 精神病性障害を治療するための方法および組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021130488A Pending JP2021181473A (ja) 2014-09-15 2021-08-10 精神病性障害を治療するための方法および組成物
JP2023168970A Pending JP2023169413A (ja) 2014-09-15 2023-09-29 精神病性障害を治療するための方法および組成物

Country Status (8)

Country Link
US (3) US20170246148A1 (https=)
EP (1) EP3194027B1 (https=)
JP (3) JP2017534673A (https=)
KR (2) KR20170066432A (https=)
AU (4) AU2015317877A1 (https=)
CA (1) CA2961380A1 (https=)
ES (1) ES3062284T3 (https=)
WO (1) WO2016044314A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104884632B (zh) * 2012-12-27 2018-01-02 索尼公司 细胞分析系统及细胞分析方法
CN105683355B (zh) 2013-11-08 2018-07-06 索尼公司 细胞分析系统、细胞分析程序和细胞分析方法
HRP20241559T1 (hr) * 2016-05-18 2025-02-14 Sound Pharmaceuticals Incorporated Ebselen za uporabu u liječenju menierove bolesti
CN107362144B (zh) * 2017-08-03 2020-04-17 华侨大学 一种鲁拉西酮脑靶向脂质体注射剂及其制备方法
GB201717629D0 (en) 2017-10-26 2017-12-13 Univ Oxford Innovation Ltd Treatment of unipolar depressive disorder
MX2020004975A (es) * 2017-11-14 2020-08-24 Sk Biopharmaceuticals Co Ltd Mezcla que contiene compuesto de carbamato para prevencion, mitigacion o tratamiento de esquizofrenia.
KR102927722B1 (ko) * 2020-05-09 2026-02-19 선전 프로파운드 뷰 파마슈티칼 테크놀로지 컴퍼니 리미티드 비정형 항정신병약물에 의해 유발되는 부작용의 치료
US20250128055A1 (en) * 2021-10-08 2025-04-24 Albert Ludwigs Universität Freiburg Treatment of psychiatric disorders with deep brain stimulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957901B1 (en) * 1996-12-31 2009-11-18 Antioxidant Pharmaceuticals Corporation Pharmaceutical preparations of glutathione and methods of administration thereof
US20050032708A1 (en) * 2001-09-27 2005-02-10 Bush Ashley I. Modulation of physiological processes and agents useful for same
US20090234011A1 (en) * 2005-04-21 2009-09-17 Goldstein Glenn A N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress
AU2006308889A1 (en) * 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20110046090A1 (en) * 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
JP2010507572A (ja) * 2006-10-23 2010-03-11 ザ メンタル ヘルス リサーチ インスティチュート オブ ビクトリア 併用療法
EP2736890A4 (en) * 2011-07-28 2015-07-15 Promentis Pharm Inc Cysteine PRODRUGS

Similar Documents

Publication Publication Date Title
JP2017534673A5 (https=)
JP2009530413A5 (https=)
JP2014517050A5 (https=)
JP2016528301A5 (https=)
JP2017521499A5 (https=)
JP2017526677A5 (https=)
JP2011508765A5 (https=)
NZ625592A (en) Compositions and methods for the treatment of hepatic diseases and disorders
JP2018030855A5 (https=)
JP2016539144A5 (https=)
JP2006523216A5 (https=)
JP2017530983A5 (https=)
JP2013542185A5 (https=)
JP7175897B2 (ja) 非アルコール性脂肪性肝炎（ｎａｓｈ）および肝線維症のための併用療法
JP2006523687A (ja) Ｉ．Ａ．シクロデキストリン、ヒドロキシ酸を含むｐＨ４〜７のフルオロキノロン水性処方
JP2021534160A5 (https=)
JP2015528501A5 (https=)
JP2011503044A5 (https=)
JP2021522247A5 (https=)
JP2015510916A5 (https=)
JP2015517523A5 (https=)
JP2005519893A5 (https=)
JP2016537432A5 (https=)
JP2021515769A (ja) カプシド集合調節剤の投薬レジメン
CN101801387A (zh) 包含喹诺酮的组合物及用于治疗或控制感染的方法